These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 29071779

  • 1. Risk factors and clinical outcomes of pediatric liver transplant recipients with post-transplant lymphoproliferative disease in a multi-ethnic Asian cohort.
    Huang JG, Tan MYQ, Quak SH, Aw MM.
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29071779
    [Abstract] [Full Text] [Related]

  • 2. Risk factors for posttransplant lymphoproliferative disorder in pediatric liver transplant recipients with cytomegalovirus antigenemia.
    Kim JM, Lee SK, Kim SJ, Joh JW, Kwon CH, Choe YH, Shin M, Kim EY, Moon JI, Jung GO, Choi GS.
    Transplant Proc; 2010 Apr; 42(3):895-9. PubMed ID: 20430199
    [Abstract] [Full Text] [Related]

  • 3. Post-transplantation lymphoproliferative disease in pediatric liver recipients in Taiwan.
    Hsu CT, Chang MH, Ho MC, Chang HH, Lu MY, Jou ST, Ni YH, Chen HL, Hsu HY, Wu JF.
    J Formos Med Assoc; 2019 Nov; 118(11):1537-1545. PubMed ID: 30630698
    [Abstract] [Full Text] [Related]

  • 4. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
    Sokal EM, Antunes H, Beguin C, Bodeus M, Wallemacq P, de Ville de Goyet J, Reding R, Janssen M, Buts JP, Otte JB.
    Transplantation; 1997 Nov 27; 64(10):1438-42. PubMed ID: 9392308
    [Abstract] [Full Text] [Related]

  • 5. EBV-PTLD, Adenovirus, and CMV in Pediatric Allogeneic Transplants With Alemtuzumab as Part of Pretransplant Conditioning: A Retrospective Single Center Study.
    Cupit-Link MC, Nageswara Rao A, Warad DM, Rodriguez V, Khan S.
    J Pediatr Hematol Oncol; 2018 Nov 27; 40(8):e473-e478. PubMed ID: 29620685
    [Abstract] [Full Text] [Related]

  • 6. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients.
    Smith JM, Corey L, Healey PJ, Davis CL, McDonald RA.
    Transplantation; 2007 Jun 15; 83(11):1423-8. PubMed ID: 17565314
    [Abstract] [Full Text] [Related]

  • 7. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
    McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, Martín MG, Bahar R, Maxfield AL, Ament ME, Busuttil RW.
    Transplantation; 1998 Dec 27; 66(12):1604-11. PubMed ID: 9884246
    [Abstract] [Full Text] [Related]

  • 8. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience.
    Narkewicz MR, Green M, Dunn S, Millis M, McDiarmid S, Mazariegos G, Anand R, Yin W, Studies of Pediatric Liver Transplantation Research Group.
    Liver Transpl; 2013 Jul 27; 19(7):730-40. PubMed ID: 23696264
    [Abstract] [Full Text] [Related]

  • 9. Comparison of Clinical Features and Outcome of Pediatric Posttransplant Lymphoproliferative Disorder in Recipients of Small Bowel Allograft Versus Isolated Liver Transplantation.
    Chiou FK, Beath SV, Morland B, Hartley J, van Mourik I, Abdel-Hady M, Kelly DA, Sharif K, Gupte GL.
    Transplantation; 2020 Jul 27; 104(7):1429-1436. PubMed ID: 31651718
    [Abstract] [Full Text] [Related]

  • 10. Effect of early EBV and/or CMV viremia on graft function and acute cellular rejection in pediatric liver transplantation.
    Indolfi G, Heaton N, Smith M, Mieli-Vergani G, Zuckerman M.
    Clin Transplant; 2012 Jul 27; 26(1):E55-61. PubMed ID: 21981027
    [Abstract] [Full Text] [Related]

  • 11. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S, Zafar MN, Best J, Reddy HK.
    J Cardiovasc Pharmacol Ther; 2006 Mar 27; 11(1):77-83. PubMed ID: 16703222
    [Abstract] [Full Text] [Related]

  • 12. Timing of Epstein-Barr virus acquisition and the course of posttransplantation lymphoproliferative disorder in children.
    Wu JF, Ho MC, Ni YH, Chen HL, Lu CY, Hsu HY, Lee PH, Chang MH.
    Transplantation; 2009 Mar 15; 87(5):758-62. PubMed ID: 19295323
    [Abstract] [Full Text] [Related]

  • 13. Transplantation for congenital heart disease is associated with an increased risk of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in children.
    Offor UT, Bacon CM, Roberts J, Powell J, Brodlie M, Wood K, Windebank KP, Flett J, Hewitt T, Rand V, Hasan A, Parry G, Gennery AR, Reinhardt Z, Bomken S.
    J Heart Lung Transplant; 2021 Jan 15; 40(1):24-32. PubMed ID: 33339556
    [Abstract] [Full Text] [Related]

  • 14. Cytomegalovirus and Epstein-Barr virus infections among pediatric kidney transplant recipients at a center using universal Valganciclovir Prophylaxis.
    Paulsen G, Cumagun P, Mixon E, Fowler K, Feig D, Shimamura M.
    Pediatr Transplant; 2019 May 15; 23(3):e13382. PubMed ID: 30786115
    [Abstract] [Full Text] [Related]

  • 15. [Remission of severe disease induced by CMV and lymphoproliferative post-transplant disease after changing the immunosuppressive regime].
    Gómez E, Melón S, Fresno MF, Tricas L, Navascués R, de Oña M, Herreros M, Alvarez Grande J.
    Nefrologia; 2002 May 15; 22(6):574-81. PubMed ID: 12516292
    [Abstract] [Full Text] [Related]

  • 16. Coinfection rates and clinical outcome data for cytomegalovirus and Epstein-Barr virus in post-transplant patients: A systematic review of the literature.
    Anderson-Smits C, Baker ER, Hirji I.
    Transpl Infect Dis; 2020 Dec 15; 22(6):e13396. PubMed ID: 32603496
    [Abstract] [Full Text] [Related]

  • 17. Increased risk of PTLD in lung transplant recipients with cystic fibrosis.
    Lowery EM, Adams W, Grim SA, Clark NM, Edwards L, Layden JE.
    J Cyst Fibros; 2017 Nov 15; 16(6):727-734. PubMed ID: 28456611
    [Abstract] [Full Text] [Related]

  • 18. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M, Desai DM, Cox KL, Berquist WE, Esquivel CO, Millan MT.
    Pediatr Transplant; 2004 Jun 15; 8(3):267-72. PubMed ID: 15176965
    [Abstract] [Full Text] [Related]

  • 19. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56dimNKG2A+KIR- NK Cells and Contributes to Suboptimal Control of EBV in Immunosuppressed Children With Post-transplant Lymphoproliferative Disorder.
    Lam JKP, Azzi T, Hui KF, Wong AMG, McHugh D, Caduff N, Chan KH, Münz C, Chiang AKS.
    Front Immunol; 2020 Jun 15; 11():1231. PubMed ID: 32625211
    [Abstract] [Full Text] [Related]

  • 20. Risk factors and long-term outcomes of pediatric liver transplant recipients with chronic high Epstein-Barr virus loads.
    Kamei H, Ito Y, Kawada J, Ogiso S, Onishi Y, Komagome M, Kurata N, Ogura Y.
    Transpl Infect Dis; 2018 Aug 15; 20(4):e12911. PubMed ID: 29677384
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.